Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells - 13/02/22
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Post-Covid pulmonary fibrosis is evident following severe COVID-19. There is an urgent need to identify the cellular and pathophysiological characteristics of chronic lung squeals of Covid-19 for the development of future preventive and/or therapeutic interventions. Tissue-resident memory T (TRM) cells can mediate local immune protection against infections and cancer. Less beneficially, lung TRM cells cause chronic airway inflammation and fibrosis by stimulating pathologic inflammation. The effects of Janus kinase (JAK), an inducer pathway of cytokine storm, inhibition on acute Covid-19 cases have been previously evaluated. Here, we propose that Tofacitinib by targeting the CD8+ TRM cells could be a potential candidate for the treatment of chronic lung diseases induced by acute SARS-CoV-2 infection.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Keywords : Pulmonary fibrosis, Coronavirus, SARS-CoV-2, JAK inhibitors, Severe lung injury
Plan
Vol 147
Article 112614- mars 2022 Retour au numéro
Article précédent
- Covalent inhibitors of EZH2: Design, synthesis and evaluation
- Qiangsheng Zhang, Xinyi Chen, Xi Hu, Xianjie Duan, Guoquan Wan, Lu Li, Qiang Feng, Yiqian Zhang, Ningyu Wang, Luoting Yu
- Protective effect of Yangxue Jiedu Soup against psoriasis-like lesions by regulating TLR4/NF-κB signaling pathway mediated by secretion of exosome HSP70
- Jingjing Lv, Yan Wang, Jingna Xu, Tao Zhou, Zhaoxia Chen, Haoyu Yang, Tingting Di, Ping Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.